Contact Us

Corporate Governance

VFP Therapies is led by a veteran team



Dr. Francis Marsais, CEO and Founder VFP Therapies

Francis Marsais, Ph.D. in Organic Chemistry, was the Managing Director of the Institut de Recherche en Chimie Organique Fine (IRCOF) from 1997 to 2010.

He also was director in charge of partnerships at INSA, Institut National des Sciences Appliquées, a major French academic engineer and research institute, from 2007 to 2011.


Francis Marsais has published over 120 official articles and holds 3 patents.




 Dr. Vincent Gembus, Chief Science Officer

Vincent Gembus received its PhD in Organic Chemistry from the Louis Pasteur University in Strasbourg (France). From 2007 to early 2012 he worked in three different postdoctoral positions at the CNRS Rouen in the COBRA team.

Vincent Gembus has published numerous papers and holds 2 patents.









Scientific Advisory Council

 VFP Therapies established a Scientific Advisory Board comprised of industry professionals and the scientific world, with a strong experience in the field scientist and wide recognition in the workplace.


This Board's role is to validate the strategic development and advice on key business decisions.


Among the members of the Scientific Council are a pharmacologist old industrial R & D Manager CNS at Sanofi-Aventis, Dr. Pascal George, a professor of medicine and pharmacy neuroscientist, Prof. Jean Costentin, a former director of INSERM biologist neuropeptides, Dr. Hubert Vaudry, and a director of Research at CNRS, Dr. Vincent Levacher.


In addition to scheduled meetings VPF Therapies management has daily interaction with the Scientific Advisory Council members.

Dr. Pascal George


Pascal George received its Ph.D. in Organic Chemistry from the Catholic University of Louvain, Belgium. He is member the prestigious Royal Society of Chemistry as well as the Society for Chemistry and Industry (SCI) – UK, the European Federation of Medicinal Chemistry (EFMC) –EU, and the American Society of Chemistry (ACS) – USA. Pascal George currently serves as President of French Medicinal Chemistry Company SCT (Société de Chimie Thérapeutique).

He is an independent scientific expert and adviser and former Research Director at Sanofi-Aventis R&D in the Central Nervous System department.



Prof. Jean Costentin


Jean Costentin is Professor of Pharmacology.
He is full member of l'Académie nationale de Pharmacie, l'Académie nationale de Médecine and member of l'Académie des Sciences, Belles Lettres et Arts de Rouen, France.

Jean Costentin is Officier de l'Ordre National du Mérite et Commandeur de l'Ordre National des Palmes Académiques.

He is the author of 310 original scientific publications in international journals with peer, author of a hundred journals in French national publications, author of four books "Brain drugs", "Stop cannabis "," Coffee, tea, chocolate, their benefits for the brain and body "," Why should not decriminalize cannabis " and a fifth to come "Dopamine in all its forms".


He is moreover author of 6 books specialized in pharmacology. His key areas of research are neurobiology of dopamine and some neuropeptides, neuropsychopharmacology in the areas of schizophrenia, depression, addictions, pain, arousal and anxiety.


Dr. Hubert Vaudry


Hubert Vaudry received his Ph. D. in 1974 and his Dr. Sci. in 1979 from the University of Rouen, Normandy, France. He spent 3 years at Queen's University, Kingston, Ontario, and Laval University, Quebec, Canada. He was recruited as Associate-Professor at the University of Rouen in 1980 and as Director of Research at INSERM in 1986.


He is currently director of the International Associated Laboratory Samuel de Champlain and director of the Platform for Cell Imaging of Haute-Normandie (PRIMACEN). Dr. Vaudry is working on the identification of novel neuropeptides and their mechanisms of action, as well as on the effects of neuropeptides on the production of neurosteroids.

He is the recipient of over twelve awards from 1983 to 2008 and has edited 22 books including 7 volumes of the Annals of the New York Academy of Sciences. He has published 950 papers that have received over 22,600 citations.

Dr. Vincent Levacher


Vincent Levacher is Director of Research at the CNRS, he received his Ph.D. in Organic Chemistry in 1992. He published over 90 papers in referred journals and holds 3 European patents.

Vincent Levacher did over 35 lectures in various French and foreign Universities and in pharmaceutical companies like Astra-Zeneca, Servier, Oril and Aventis-Sanofi. Vincent Levacher is scientific manager of the Heterocyclic team at COBRA since 2009, coordinator of the Heterocyclic Chemistry axis of the Labex SYNORG since 2012, coordinator of the valorization department of the Labex SYNORG since 2012 and director of the joint JANSSEN-COBRA laboratory since 2007.

Dr. Thierry Besson



Thierry Besson holds a DEA of Biophysicochemistry, Cellular and Molecular Biology from University of Orléans. After is PhD in chemistry (1989-1992), he joined the group of Prof. Charles W. Rees at Imperial College in London where he stay until is integration in the staff of the new University of La Rochelle, at the end of 1993. After five years of research and teaching as lecturer and then assistant-professor, he was elected in 1999 as full-Professor of organic chemistry until 2006 where he moved as Professor of medicinal chemistry to the Faculty of Medicine and Pharmacy of Rouen in Normandy. His research interest includes the use of special heterocyclic reagents applied to the synthesis of bio-active molecules, inspired by marine or terrestrial alkaloids, with a particular emphasis on microwave-assisted chemistry. Since 1990, Thierry Besson and his co-workers published more than 100 papers and holds 1 patent in the domain of microwave assisted medicinal chemistry.






Dr. Pierre Bohn

Radio-pharmacist at cancer research center Henri Becquerel
2008 winner of the National Academy of Pharmacy in physicochemical sciences
Pierre Bohn holds Ph.D.'s in Pharmacy and in Organic Chemistry
His dual expertise in pharmacy and chemistry is a very important asset for VFP Therapies.


Pierre Bohn also manages the micro gamma camera imagery center of the Faculty of Medicine and Pharmacy in Rouen. He published over 10 scientific papers and co-holds one patent.

2021 © VFP Therapies Hébergement & Support Le plus du Web - Création graphique Pratikmedia